Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation, potential implications for COX-2 inhibition

Recent increased adverse cardiovascular events observed with selective cyclooxygenase-2 (COX-2) inhibition led to the withdrawal of rofecoxib (Vioxx) and valdecoxib (Bextra), but the mechanisms underlying these atherothrombotic events remain unclear. Prostacyclin is the major endproduct of COX-2 in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Arehart, Eric, Stitham, Jeremiah, Asselbergs, Folkert W., Douville, Karen, MacKenzie, Todd, Fetalvero, Kristina M., Gleim, Scott, Kasza, Zsolt, Rao, Yamini, Martel, Laurie, Segel, Sharon, Robb, John, Kaplan, Aaron, Simons, Michael, Powell, Richard J., Moore, Jason H., Rimm, Eric B., Martin, Kathleen A., Hwa, John
Formato: Artigo
Lenguaje:Inglês
Publicado: 2008
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2793685/
https://ncbi.nlm.nih.gov/pubmed/18323528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCRESAHA.107.165936
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares